HC Wainwright Has Optimistic Outlook of BBIO Q2 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Monday, June 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.87) for the quarter, up from their previous estimate of ($1.08). HC Wainwright currently has a "Buy" rating and a $56.00 price target on the stock. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma's Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.44) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($2.10) EPS.

Several other equities research analysts have also recently weighed in on the stock. Wall Street Zen raised shares of BridgeBio Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Cantor Fitzgerald reiterated an "overweight" rating and set a $95.00 target price on shares of BridgeBio Pharma in a report on Friday, February 21st. Citigroup raised their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. UBS Group upped their price target on BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. Finally, Redburn Atlantic initiated coverage on BridgeBio Pharma in a report on Monday, March 31st. They issued a "buy" rating and a $50.00 price objective for the company. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $57.36.

BridgeBio Pharma Stock Up 0.9%

Shares of BridgeBio Pharma stock traded up $0.36 on Wednesday, hitting $39.41. The stock had a trading volume of 581,026 shares, compared to its average volume of 2,474,108. BridgeBio Pharma has a one year low of $21.62 and a one year high of $40.40. The stock's 50-day simple moving average is $34.92 and its two-hundred day simple moving average is $32.91. The stock has a market cap of $7.48 billion, a price-to-earnings ratio of -13.83 and a beta of 1.10.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million for the quarter, compared to analysts' expectations of $57.14 million. The company's revenue was down 44.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.20) earnings per share.

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 26,156 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $33.33, for a total value of $871,779.48. Following the completion of the transaction, the chief executive officer now directly owns 217,404 shares in the company, valued at $7,246,075.32. This trade represents a 10.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Andrea Ellis sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $35.00, for a total transaction of $350,000.00. Following the transaction, the director now directly owns 12,000 shares of the company's stock, valued at $420,000. This represents a 45.45% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,396,474 shares of company stock valued at $219,332,971. Corporate insiders own 18.20% of the company's stock.

Hedge Funds Weigh In On BridgeBio Pharma

Several institutional investors and hedge funds have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC grew its position in BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock valued at $28,000 after purchasing an additional 472 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of BridgeBio Pharma by 71.0% during the first quarter. GAMMA Investing LLC now owns 920 shares of the company's stock valued at $32,000 after purchasing an additional 382 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of BridgeBio Pharma during the 1st quarter valued at $35,000. Itau Unibanco Holding S.A. purchased a new position in shares of BridgeBio Pharma in the 4th quarter worth $41,000. Finally, Sterling Capital Management LLC grew its holdings in shares of BridgeBio Pharma by 554.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after acquiring an additional 1,514 shares during the period. 99.85% of the stock is currently owned by institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.